Biotron Ltd., of Sydney, Australia, initiated a randomized, double-blind, placebo-controlled, multicenter phase II trial (BIT225-009) with lead antiviral drug, BIT225, together with the combination antiretroviral therapy Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate, Gilead Sciences Inc.), in treatment-naïve patients with HIV-1 infection.